A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis

OBJECTIVES: The aim of this report is to demonstrate pharmacokinetic (PK) and pharmacodynamic (PD) equivalence as well as similar efficacy, safety and immunogenicity between GP2013, a biosimilar rituximab, and innovator rituximab (RTX) in patients with rheumatoid arthritis (RA) with inadequate respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S, Cohen, Stanley B, Tony, Hans-Peter, Scheinberg, Morton, Kivitz, Alan, Balanescu, Andra, Gomez-Reino, Juan, Cen, Liyi, Zhu, Peijuan, Shisha, Tamas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Annals of the Rheumatic Diseases 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561377/
https://www.ncbi.nlm.nih.gov/pubmed/28637670
http://dx.doi.org/10.1136/annrheumdis-2017-211281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561377/
https://www.ncbi.nlm.nih.gov/pubmed/28637670
http://dx.doi.org/10.1136/annrheumdis-2017-211281

Ejemplares similares